Your browser is out-of-date!

Update your browser to view this website correctly.

1Cookies

2Disclaimer

BB Biotech AG publishes its 2022 annual report

Annual report of BB Biotech AG as at December 31, 2022
17.02.2023

Ad hoc announcement pursuant to Art. 53 LR

BB Biotech AG published its annual report for fiscal year 2022 today. Besides the audited consolidated financial statements, the annual report contains detailed information on the biotechnology sector, BB Biotech’s positioning, the investment areas covered by its portfolio and the companies it is invested in.

The year 2022 saw volatile market conditions for global equity and bond markets, with substantial stepwise increases in central bank rates, led by the US Federal Reserve Bank. The biotech stocks showed a mixed performance. Large caps gained value throughout 2022, while some small and mid caps experienced significant corrections. For the full year, BB Biotech’s total share return was ‑24.3% in CHF and -19.0% in EUR, substantially behind the portfolio performance of -11.0% in CHF, -6.7% in EUR and -12.1% in USD. The net loss for BB Biotech in 2022 was CHF 358 mn.

As already announced on January 20, 2023, BB Biotech will propose a dividend of CHF 2.85 per share at the upcoming Annual General Meeting, which represents a yield of 5% based on the volume-weighted average price of BB Biotech shares in December 2022. This marks a continuation of the dividend policy of the previous years.

BB Biotech’s annual report 2022 is available under report.bbbiotech.ch/2022/en resp. www.bbbiotech.com

 

For further information:

Investor Relations

Bellevue Asset Management AG 
Seestrasse 16, 8700 Küsnacht, Switzerland, tel. +41 44 267 67 00
Dr. Silvia Siegfried-Schanz, ssc@bellevue.ch
Maria-Grazia Alderuccio, mga@bellevue.ch
Claude Mikkelsen, cmi@bellevue.ch

 

Media Relations
Bellevue Asset Management AG
Seestrasse 16, 8700 Küsnacht, Switzerland, tel. +41 44 267 67 00
Tanja Chicherio, tch@bellevue.ch

TE Communications AG, Bleichestrasse 11, 9000 St. Gallen, Switzerland, tel. +41 79 423 22 28
Thomas Egger, teg@te-communications.ch